Copyright
©The Author(s) 2019.
World J Meta-Anal. Jun 30, 2019; 7(6): 269-289
Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.269
Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.269
Table 3 Morbidity, mortality and survival rates after multivisceral resection for colon and rectal cancer
Study | Follow-up (mo) | Morbidity (%) | Mortality (%) | Survival1 | Stage IV disease (%) | True pT4b (%) |
Cukier et al[24] | 36 | 36 | 0 | 3-yr OS: 85.9%; 3-yr DFS: 73.7% | 0 | 67 |
Hallet et al[20] | 54 | 33.3 | 0 | 90%; 5-yr DFS: 63.5% | 0 | 50 |
Kumamoto et al[15] | 32 | 17.8 | 0.8 | 87% | 12 | 45 |
Leijssen et al[2] | 48.5 | 25 | 0 | 5-yr OS (pT3): 63%; 5-yr OS (pT4): 70% | 0 | 24 |
López-Cano et al[49] | 74.9 | 47.8 | 7.1 | 48%; 5-yr DFS: 46.3 mo | 20 | 65 |
Rosander et al[7] | 28 | 37% (≥ Grade III) | 5 | 60.8% for the infiltration group; 86.9% for the inflammation group | 0 | 63 |
Takahashi et al[12] | 48.4 | LAP: 7 OPEN: 36 | 0 | 3-ys OS (open): 79.8%; (lap): 92.8% | 25 | 50 |
Tei et al[23] | 34 | 37.9 | 0 | 3-yr OS Stage II-III (S-MVR/M-MVR): 81.8%/80.0% 3-yr DFS Stage II-III (S-MVR/M-MVR: 58.3%/70.0% | 28 | 34 |
Chen et al[6] | NR | 11.5 | NR | 59% (Colon/inflammation) 39% (Colon/invasion) 63% (Rectum/inflammation); 42% (Rectum/invasion) | 54 | 55 |
Eveno et al[58] | 48 | 12 | 1.3 | 77%; 3-yr OS (without stage IV disease): 89%; 5-yr DFS: 58% | 13 | 65 |
Fujisawa et al[29] | 42 (mean) | NR | NR | 3-yr OS (colon/bladder sparing): 90%; (colon/nonsparing): 67%; 3 yr OS (rectal/bladder sparing): 50%; (rectal/nonsparing): 67% | NR | NR |
Hoffmann et al[21] | NR | 34.6 | 7.7 | 55% (if curative) | 49 | 63 |
Gezen et al[18] | 25 (mean) | 24.4 | 4.4 | 69.4% | 12 | 34 |
Kim et al[17] | 35/40 (mean) | LAP: 21 OPEN: 44 | 0 | LAP: 60.5%; OPEN 48% | 33 | 44 |
Laurence et al[56] | NR | NR | NR | 52.7% | 3 | NR |
Lehnert et al[8] | 71 | 33 | 7.5 | 51% | 5 | 50 |
Li et al[16] | 64.3 | 61 | 5.6 | 50%; 59%: if curative | 21 | 47 |
Park et al[53] | NR | 35.2 | 3.1 | 58% | 0 | 44 |
Rizzuto et al[57] | NR | 55 | 0 | 3-yr OS (non-occlusive): 58.4%; (occlusive): 33.3% | 0 | 77 |
Winter et al[1] | 84 | 18 | 1.5 | 57%; 61% (R0); 17% (R1) 77% (R0, N0); 28% (R0, N+) | NR | 54 |
Banmura et al[56] | 32 | 50 | 0 | Local recurrence rate: 30% | 33 | 63 |
Crawshaw et al[25] | 27.8 | 57.4 | 0 | 49.2%; 5-yr DFS: 45.3% | 0 | 39 |
Derici et al[48] | 40.4 (mean) | 38.6 | 3.5 | 49%; 3-yr OS: 81.6% | 0 | 58 |
Dinaux et al[50] | 38.2 | 72.4 | 0 | OS: 45 mo | 0 | 24 |
Dosokey et al[30] | 32 (mean) | 39 | 0 | 67%; 5-yr DFS: 79% | 0 | NR |
Gannon et al[28] | 40 | 43 | 0 | 48%; Primary: 65% Recurrent: 22%; 5-yr DFS. 38%; Primary: 52% Recurrent: 13% | NR | NR |
Harris et al[19] | 30 | 50 | 0 | 5-yr OS (R0): 48%; R1/R2: 33% | 14 | 52 |
Ishiguro et al[54] | 40 | 39.8 | 2.2 | 52%; 5-yr DFS: 46% | NR | 49 |
Mañas et al[13] | 28.8 | 76.6 | 10 | 36.7% | 20 | 67 |
Nielsen et al[9] | 12 | 51 | 2.2 | 5-yr OS (primary): 46%; (recurrent):17% | 0 | NR |
Pellino et al[14] | NR | 54.9 | 2.4 | 67% | NR | 70 |
Rottoli et al[10] | 32.5/56.6 | 33 Primary: 32% Recurrent: 33% | 4 | 5-yr DFS (primary): 46% (recurrent): 24% | NR | NR |
Sanfilippo et al[51] | NR | 25 | NR | 4-yr OS: 69% | 0 | 44 |
Shin et al[22] | 30 | 41.7 | 0 | 80% | 27 | 23 |
Smith et al[47] | NR | 47.6 | 0.8 | 53.3%; M0: 59% | 20 | 44 |
Vermaas et al[11] | 28 (mean) | 69; Primary: 61; Recurrent: 83 | 3 | 52% (primary); 3-yr OS (recurrent): 32% | NR | 43 |
- Citation: Nadiradze G, Yurttas C, Königsrainer A, Horvath P. Significance of multivisceral resections in oncologic surgery: A systematic review of the literature. World J Meta-Anal 2019; 7(6): 269-289
- URL: https://www.wjgnet.com/2308-3840/full/v7/i6/269.htm
- DOI: https://dx.doi.org/10.13105/wjma.v7.i6.269